Business Description
Molecular Partners AG
ISIN : CH0256379097
Compare
Compare
Traded in other countries / regions
MOLN.SwitzerlandMOLN.USAMOLNz.UK6ML0.Germany IPO Date
2014-11-05Description
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 51.17 | |||||
| Equity-to-Asset | 0.89 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.06 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 1.61 | |||||
| Beneish M-Score | 36.91 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -16.9 | |||||
| 3-Year EBITDA Growth Rate | 8.7 | |||||
| 3-Year EPS without NRI Growth Rate | 9.4 | |||||
| 3-Year FCF Growth Rate | -14.1 | |||||
| 3-Year Book Growth Rate | 13.4 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 51.5 | |||||
| 9-Day RSI | 47.03 | |||||
| 14-Day RSI | 45.74 | |||||
| 6-1 Month Momentum % | 15.5 | |||||
| 12-1 Month Momentum % | -34.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.35 | |||||
| Quick Ratio | 13.35 | |||||
| Cash Ratio | 12.96 | |||||
| Days Sales Outstanding | 60.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.1 | |||||
| Shareholder Yield % | 1.14 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -868.26 | |||||
| Net Margin % | -880.71 | |||||
| FCF Margin % | -849.86 | |||||
| ROE % | -29.92 | |||||
| ROA % | -26.86 | |||||
| ROIC % | -459.08 | |||||
| ROC (Joel Greenblatt) % | -969.18 | |||||
| ROCE % | -28.77 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 15.62 | |||||
| PB Ratio | 0.63 | |||||
| Price-to-Tangible-Book | 0.63 | |||||
| EV-to-EBIT | 1.18 | |||||
| EV-to-Forward-EBIT | 0.85 | |||||
| EV-to-EBITDA | 1.22 | |||||
| EV-to-Forward-EBITDA | 0.4 | |||||
| EV-to-Revenue | -10.34 | |||||
| EV-to-Forward-Revenue | 0.31 | |||||
| EV-to-FCF | 1.31 | |||||
| Price-to-Projected-FCF | 1.25 | |||||
| Price-to-Net-Current-Asset-Value | 0.65 | |||||
| Price-to-Net-Cash | 0.67 | |||||
| Earnings Yield (Greenblatt) % | 85.1 | |||||
| FCF Yield % | -54.16 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Molecular Partners AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil CHF) | 7.038 | ||
| EPS (TTM) (CHF) | -1.89 | ||
| Beta | 0.43 | ||
| Volatility % | 46.64 | ||
| 14-Day RSI | 45.74 | ||
| 14-Day ATR (CHF) | 0.181749 | ||
| 20-Day SMA (CHF) | 3.43525 | ||
| 12-1 Month Momentum % | -34.14 | ||
| 52-Week Range (CHF) | 3.04 - 6.3 | ||
| Shares Outstanding (Mil) | 32.87 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Molecular Partners AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Molecular Partners AG Stock Events
| Event | Date | Price(CHF) | ||
|---|---|---|---|---|
| No Event Data | ||||
Molecular Partners AG Frequently Asked Questions
What is Molecular Partners AG(XSWX:MOLN)'s stock price today?
The current price of XSWX:MOLN is CHF3.36. The 52 week high of XSWX:MOLN is CHF6.30 and 52 week low is CHF3.04.
When is next earnings date of Molecular Partners AG(XSWX:MOLN)?
The next earnings date of Molecular Partners AG(XSWX:MOLN) is 2024-08-26.
Does Molecular Partners AG(XSWX:MOLN) pay dividends? If so, how much?
Molecular Partners AG(XSWX:MOLN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers